CAS · 162401-32-3
Product Overview
Roflumilast is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Appearance: | White or off-white powder |
|---|---|
| Purity: | 99.0% min |
| Assay: | 98-102% |
| Melting point: | 153-158℃ |
| Water: | 0.5% max |
| Single impurity: | 0.3% max |
| Total impurities: | 1.0% max |
| Residue on ignition: | 0.5% max |
| THF: | 0.072% max |
| Ethyl acetate: | 0.5% max |
| Methanol: | 0.3% max |
| Ethanol: | 0.5% max |
| Toluene: | 0.089% max |
| DMF: | 0.088% max |
| Identification: | Complies |
Applications
1. Chronic Obstructive Pulmonary Disease (COPD)
Primary indication for reducing the risk of COPD exacerbations in patients with:
Severe COPD (FEV1 < 50%)
Chronic bronchitis phenotype
History of frequent exacerbations
Mechanism: PDE4 inhibition leads to increased cAMP in neutrophils, eosinophils, macrophages, and T cells, suppressing pro-inflammatory cytokine release and reducing airway inflammation.
2. Asthma (Investigational)
Studied for use in severe asthma, especially phenotypes with eosinophilic or neutrophilic inflammation.
Shows promise in combination therapy with corticosteroids.
3. Other Inflammatory Disorders (Preclinical/Research)
Being investigated for potential roles in:
Psoriasis
Pulmonary fibrosis
Inflammatory bowel disease (IBD)
Neuroinflammatory conditions such as multiple sclerosis or Alzheimer's disease
Benefits
1. Selective PDE4 Inhibition
Roflumilast丨CAS 162401-32-3 provides targeted anti-inflammatory activity in the lungs without affecting PDE1–3 or PDE5 pathways.
Reduces airway neutrophilic inflammation, complementing bronchodilators.
2. Oral Once-Daily Dosing
Convenient oral tablet, usually 500 µg once daily, improves patient adherence compared to inhaled therapies.
3. Steroid-Sparing Potential
Non-corticosteroid anti-inflammatory action reduces reliance on inhaled or systemic corticosteroids, which have more side effects.
4. Exacerbation Risk Reduction
Demonstrated efficacy in reducing moderate-to-severe COPD exacerbations, especially in high-risk patients with chronic bronchitis.
Conclusion
A concise summary and suitability assessment for this product is available on request. Contact our team to discuss whether it fits your process and quality requirements.